{
  "abstract": "INTRODUCTION: Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD‐GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people with heterozygous loss‐of‐function (LOF) GRN mutations.\n\nMETHODS: A pivotal phase 3 trial, INFRONT‐3 (NCT04374136), evaluated the efficacy, safety, and biomarker changes of 60 mg/kg of intravenously administered latozinemab or placebo every 4 weeks for 96 weeks in participants who have or are at risk for FTD due to heterozygous LOF GRN mutations. Those completing the double‐blind phase could enter a 96‐week open‐label safety extension.\n\nRESULTS: Although latozinemab administration resulted in sustained elevation of plasma and CSF PGRN concentrations in symptomatic participants with FTD‐GRN (primary analysis population), there was no treatment‐related slowing of disease progression as measured by clinical or biomarker assessments. No adverse safety signals were identified.\n\nDISCUSSION: INFRONT‐3 provides the first phase 3 efficacy and safety results for an investigational therapy in FTD‐GRN.",
  "abstract_shown": true,
  "affiliations": [
    "Alector, Inc. South San Francisco California USA",
    "Department of Neurology Mayo Clinic Rochester Minnesota USA",
    "Paris Brain Institute Pitié‐Salpêtrière Hospital Paris France",
    "Department of Clinical and Experimental Sciences University of Brescia Brescia Italy",
    "IRCCS Centro San Giovanni di Dio Fatebenefratelli Molecular Markers Laboratory Brescia Italy",
    "Dementia Research Centre, National Hospital for Neurology and Neurosurgery University College London Hospital London UK",
    "Dementia Research Centre, Queen Square Institute of Neurology University College London London UK",
    "Department of Biomedical Metabolic and Neural Sciences at the University of Modena and Reggio Emilia Modena Italy",
    "Department of Neurology, Faculty of Medicine and University Hospital Cologne University of Cologne Cologne Germany",
    "Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge Cambridge UK",
    "Weill Institute for Neurosciences University of California San Francisco San Francisco California USA",
    "Mariner Bio Consulting LLC Mill Valley California USA",
    "Neurocrine Biosciences San Diego California USA",
    "Everest Clinical Research Markham Ontario Canada",
    "Mirum Pharmaceuticals Foster City California USA",
    "Eli Lilly Indianapolis Indiana USA",
    "Aditum Bio Oakland California USA"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 31,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Adam Simmons",
      "orcid": "0009-0005-6809-0967"
    },
    {
      "affs": [
        1
      ],
      "name": "Bradley Boeve"
    },
    {
      "affs": [
        2
      ],
      "name": "Isabelle Le Ber"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Barbara Borroni"
    },
    {
      "affs": [
        5
      ],
      "name": "Catherine Mummery"
    },
    {
      "affs": [
        6
      ],
      "name": "Jonathan D. Rohrer"
    },
    {
      "affs": [
        7
      ],
      "name": "Giovanna Zamboni"
    },
    {
      "affs": [
        8
      ],
      "name": "Oezguer A. Onur"
    },
    {
      "affs": [
        9
      ],
      "name": "James B. Rowe"
    },
    {
      "affs": [
        10
      ],
      "name": "Adam L. Boxer"
    },
    {
      "affs": [
        11
      ],
      "name": "Tina Schwabe"
    },
    {
      "affs": [
        0
      ],
      "name": "Olga I. Kahn"
    },
    {
      "affs": [
        12
      ],
      "name": "Julie Y. Huang"
    },
    {
      "affs": [
        0
      ],
      "name": "Hua Long"
    },
    {
      "affs": [
        0
      ],
      "name": "Ruchi Gupta"
    },
    {
      "affs": [
        0
      ],
      "name": "Jinglin Zhong"
    },
    {
      "affs": [
        0
      ],
      "name": "Caiyan Li"
    },
    {
      "affs": [
        13
      ],
      "name": "Leonard Guizzetti"
    },
    {
      "affs": [
        14
      ],
      "name": "Lawrence P. Carter"
    },
    {
      "affs": [
        0
      ],
      "name": "Tuan Nguyen"
    },
    {
      "affs": [
        0
      ],
      "name": "Tiffany W. Chow"
    },
    {
      "affs": [
        0
      ],
      "name": "Balasubrahmanyam Budda"
    },
    {
      "affs": [
        15
      ],
      "name": "Lovingly Park"
    },
    {
      "affs": [
        16
      ],
      "name": "Sam Jackson"
    },
    {
      "affs": [
        0
      ],
      "name": "Robert Paul"
    },
    {
      "affs": [
        0
      ],
      "name": "Michael Ward"
    },
    {
      "affs": [
        0
      ],
      "name": "Gary Romano"
    },
    {
      "affs": [
        0
      ],
      "name": "Sara Kenkare‐Mitra"
    },
    {
      "affs": [
        0
      ],
      "name": "Arnon Rosenthal"
    },
    {
      "affs": [
        0
      ],
      "name": "Giacomo Salvadore"
    },
    {
      "affs": [
        0
      ],
      "name": "Arthur J. Mayorga"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/70tftshw64dnc.bib",
  "cited_by": 0,
  "doi": "10.1002/alz.71947",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13710668/",
  "id": "70tftshw64dnc",
  "issns": [
    "1552-5260",
    "1552-5279"
  ],
  "landing_url": "https://doi.org/10.1002/alz.71947",
  "language": "en",
  "licence": "CC-BY-NC-4.0",
  "licence_label": "CC BY-NC 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research Article"
    ],
    [
      "openalex",
      "2728|Amyotrophic Lateral Sclerosis Research"
    ]
  ],
  "openalex": "W7223975655",
  "pdf_url": "https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.71947",
  "pmcid": "PMC13710668",
  "pmid": "42934864",
  "published": "2026-10-26",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/70tftshw64dnc.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T12:21:35Z",
      "native_id": "PMC13710668",
      "source": "pmc",
      "url": "https://doi.org/10.1002/alz.71947"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2728|Amyotrophic Lateral Sclerosis Research",
      "subfield": "neurology"
    }
  ],
  "title": "Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations",
  "title_text": "Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:21:35Z",
  "url": "https://research.draconitic.com/paper/70tftshw64dnc",
  "venue": "Alzheimer's & Dementia",
  "versions": []
}